Small molecule inhibitors of protein kinases

1. A method of inhibiting degranulation, inhibiting respiratory burst, or inhibiting Syk phosphorylation by administering a compound of Formula b) or its isomeric form, to a patient in need of such inhibition, wherein inhibition of degranulation, respiratory burst, or Syk phosphorylation is effective for treating cancer or other proliferative disease, genitourinary disease, hepatic disease, pancreatic disease, pulmonary disease, gastrointestinal disease, osteoporosis, inflammation, allergic reaction, or cardiovascular disease, in the patient, and wherein the compound of Formula b) or its isomeric form have the following formulas:

Formula b)

or:

wherein:

R 1 and R 2 are independently selected from the group consisting of —C(O)OR 5 , —C(S)OR 5 , —C(NR 5 )OR 5 , —C(O)SR 5 , —C(S)SR 5 , —C(NR 5 )SR 5 , —C(O)N(R 5 ) 2 , —C(S)N(R 5 ) 2 , —C(NR 5 )N(R 5 ) 2 ,—N(R 5 )C(O)OR 5 , —N(R 5 )C(S)OR 5 , —N(R 5 )C(NR 5 )OR 5 , —N(R 5 )C(O)SR 5 , —N(R 5 )C(S)SR 5 , —N(R 5 )C(NR 5 )SR 5 , —N(R 5 )C(O)N(R 5 ) 2 , —N(R 5 )C(S)N(R 5 ) 2 , —N(R 5 )C(NR 5 ) N(R 5 ) 2 , —NO 2 , —SOR 5 , —SO 2 R 5 , —SO 3 R 5 , —CN, —PO 4 R 5 , —C(O)R 5 , —C(S)R 5 , and —C(NR 5 )R 5 ,

Y is O, S, or NR 5 ,

R 5 is a substituent selected from the group consisting of H, —C 1-6 alkyl, —C 1-6 alkylaryl, -aryl-C 1-6 alkyl, —C 1-6 alkylheteroaryl, -heteroaryl-C 1-6 alkyl, -aryl, and -heteroaryl,

R 6 is C 1-6 -alkylaryl, C 1-6 -alkylheteroaryl, aryl, or heteroaryl, wherein the aryl or heteroaryl ring in the aryl, aralkyl, alkheteroaryl, or heteroaryl substituents is optionally substituted with one to three substituents, Z, as described above, wherein in one embodiment, the substituent,

Z, is a substituent defined as R 2 herein, and in another embodiment, is defined as being selected from the group consisting of C(S)OR 5 , —C(NR 5 )OR 5 , —C(O)SR 5 , —C(S)SR 5 , —C(NR 5 )SR 5 , —C(O)N(R 5 ) 2 , —C(S)N(R 5 ) 2 , —C(NR 5 )N(R 5 ) 2 , —N(R 5 )C(O)OR 5 , —N(R 5 )C(S)OR 5 , —N(R 5 )C(NR 5 )OR 5 , —N(R 5 )C(O)SR 5 , —N(R 5 )C(S)SR 5 , —N(R 5 )C(NR 5 )SR 5 , —N(R 5 )C(O)N(R 5 ) 2 , —N(R 5 )C(S)N(R 5 ) 2 , —N(R 5 )C(NR 5 ) N(R 5 ) 2 , —SOR 5 , —SO 2 R 5 , —SO 3 R 5 , —PO 4 R 5 , —C(O)R 5 , —C(S)R 5 , and —C(NR 5 )R 5 , and

R 7 is a substituent selected from the group consisting of H, —C 1-6 alkyl, —C 1-6 alkylaryl, -aryl-C 1-6 alkyl, —C 1-6 alkylheteroaryl, -heteroaryl—C 1-6 alkyl, -aryl, and -heteroaryl, and

polymorphs, salts, hydrates, and solvates thereof, wherein the compound is a kinase inhibitor.

2. The method of claim 1 , wherein the patient is a human suffering from a condition selected from the group consisting of an allergic disease, low grade scarring, a disease associated with tissue destruction, a disease associated with tissue inflammation, and inflammation.

3. The method of claim 2 , wherein the inflammation is caused by a disorder selected from the group consisting of conjunctivitis, rhinitis, asthma, atopic dermatitis and food allergies.

4. The method of claim 2 , wherein the disease associated with tissue inflammation is selected from the group consisting of irritable bowel, spastic colon, inflammatory colon disease, vasculitis, lupus, gout and rhuematoid arthritis.

5. The method of claim 1 , wherein the compound has the following formula:

wherein Y, R 1 and R 6 are as defined in claim 1 .

6. The method of claim 1 , wherein the compound has the following formula:

wherein Y, R 5 and R 6 are as defined in claim 1 .

7. The method of claim 1 , wherein the compound has the following formula:

wherein:

Z is selected from the group consisting of C 1-6 alkyl, alkenyl, heterocyclyl, aryl, heteroaryl, halo, —OR′, —NR′R″, —CF 3 , —CN, —NO 2 , —C 2 R′, —SR′, —N 3 , —C(═O)NR′R″, —NR′C(═O) R″, —C(═O)R′, —C(═O)OR′, —OC(═O)R′, —OC(═O)NR′R″, —NR′C(═O)O R″, —SO 2 R′, —SO 2 NR′R″, and —NR′SO 2 R″, where R′ and R″ are individually hydrogen, C 1-6 alkyl, cycloalkyl, heterocyclyl, aryl, or arylalkyl, wherein the aryl or heteroaryl rings can be substituted at any free position with Z,

j is an integer from 0 to the number of available positions on the aryl or heteroaryl ring to which the Z substituent is attached,

X is, individually, N, or C bonded to H or a substituent Z, and, in one embodiment, no more than two X are N within any ring structure, and

n is an integer of from 1 to 3.

8. The method of claim 1 , wherein the compound has the following structure:

wherein R 2 and Y are as defined in claim 1 .

9. The method of claim 1 , wherein the compound has the following structure: